In Depth 23 Jan 2018 Walking with the Dinosaurs of European Biotech: Which of Them is Roaring the Loudest? …infectious diseases. Somewhat of a sleeping giant, the company has yet to bring a drug to market, which no doubt contributes to its falling market cap, now standing at €176M… January 23, 2018 - 10 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2018 Enterome Brings in a €32M Series D for its Microbiome-Based Therapies …in the exciting field of microbiome-based therapies for diseases like inflammatory bowel diseases and cancer. This morning, the company has announced that it has raised €32M in a Series D… January 4, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 4 Nov 2020 The Return of Gene Therapy …a smooth one. Gene therapy has been one of the biggest success stories of the 21st century. Genetic diseases were once seen as incurable, etched in stone (or rather, in… November 4, 2020 - 8 minutesmins - By Farhan Mitha Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2023 A gene editing milestone: The FDA approves CASGEVY, the first CRISPR-based therapy Still a relatively new technology, CRISPR has been heralded in recent years as having the potential to tackle a range of diseases. And now, it has finally proved its worth…. December 6, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 Spinoff Biohaven launches with $258M and “incredible pipeline” Biohaven Ltd. launched today as a new publicly traded company focused on delivering innovative life-changing treatments for neurological and neuropsychiatric diseases, including rare disorders. As of today, Biohaven has officially… October 4, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 11 Jul 2023 Unlocking the power of mRNA technology …are used to train the immune system against specific viruses without exposing the body to live pathogens. This breakthrough approach has provided a foundation for combating infectious diseases. Another significant… July 11, 2023 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 21 Apr 2021 Changing Attitudes on Vaccine and Public Health Investment …predominantly defined as high-burden and neglected infectious diseases,” he explained. “Not being very creative as bankers, we said, ‘why don’t you sponsor the creation of an investment fund and demonstrate… April 21, 2021 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Sponsored by Hub Organoids 12 Jul 2022 The organoid era: bringing patient-relevant preclinical models to the lab …of human diseases, noted Federica Parisi, Marketing and Sales Manager at HUB Organoids. “We have used organoids to study diseases beyond oncology — such as cystic fibrosis or irritable bowel… July 12, 2022 - 7 minutesmins - By Sudha Sundaram Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2022 Licensing agreement signed for C4XD between C4X Discovery and AstraZeneca …therapy, C4XD. This is for the treatment of inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD). C4X Discovery will receive pre-clinical milestone payments worth up… November 28, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2017 Giving Molecular Combing the Golden Coat It Deserves …of different diseases. A golden coat for a long-lasting effect Molecular combing of DNA can be used for the analysis of genome variations, as well as gene editing, cancer diagnosis… December 19, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
More News! 4 Jan 2018 Belgian Biotech Hits ‘Fast Forward’ on Multiple Sclerosis Therapies …multiple sclerosis and other myelin-related diseases. Rewind will use the money to move its first small molecule product to the clinic and to expand its pipeline. Multiple sclerosis is caused… January 4, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2020 Therachon Founders Spin Out New Rare Disease Biotech With €31M Investment …diseases in the future. “Rare diseases remain an area of significant unmet medical need, where our team’s proven track record and entrepreneurial mindset will enable us to have a positive… January 8, 2020 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email